FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011393277> ?p ?o ?g. }

• W3011393277 abstract "3098 Background: Histone deacetylase and mTOR inhibition circumvent critical EBV-oncogenic pathways with preclinical studies demonstrating lytic induction in EBV infected cells, as well as immunomodulatory and antiangiogenic effects. Methods: Patients (Pt) with advanced solid tumors enriched for EBV–related cancers were enrolled to determine safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics and preliminary antitumor activity. LBH was instituted 7-days prior to combination treatment. NPC pt received antiviral prophylaxis of either acyclovir (Ac) or valaciclovir (Vc). Serum EBV DNA levels (EBNA-1) were measured weekly and plasma cytokines profiled using a 31-plex Luminex panel. Results: 15 pt have been treated (M:F 13:2, median age 50, R: 38-63) 10 NPC, 5 non-NPC (colon, RCC, breast, gastric, sarcoma) at 3 dose levels – LBH (3x/wk)-EVE (daily):10-2.5, 10-5, 15-5. Two dose limiting toxicities of G4 (grade) thrombocytopenia were observed at LBH15-RAD5. Significant adverse events (AE) (G≥3) were dysphagia (1) and thrombocytopenia (3). Common AEs (G1/2) included fatigue (80%), anorexia (60%), mucositis (53%), xerostomia (26%), dysphagia (26%). Two minor responses were seen (1 NPC, 1 breast) and 2 pt (1 NPC, 1 RCC) had prolonged stable disease (>16 weeks). Modulation of EBV DNA titres was seen only in NPC pt, with median fold-change from baseline of 10.9 (0.05-174). Pt on Ac prophylaxis (n=5) had significant increases in DNA titres (9-174 fold), while those on Vc (n=4) were less pronounced (0.05-11 fold, p<0.03), with one pt (with minor response) having persistent decline in EBV titres. In a limited pt subset (n=9, 30 timepoints), plasma cytokine profiles were consistent with a T-cell response, specifically, elevated levels of FLT3L, IFN-gamma, IL-13 and IL-17. PK and PBMC target modulation studies are being analysed. Conclusions: LBH-EVE results in induction of EBV DNA titres with an associated host T cell response. MTD is LBH10-EVE5 in Asian pt, majority of whom had NPC. A pre-planned expansion cohort that incorporates multi-parametric functional imaging exploring two schedules of LBH in combination with EVE5 is ongoing." @default.
• W3011393277 created "2020-03-23" @default.
• W3011393277 creator A5001623814 @default.
• W3011393277 creator A5017520870 @default.
• W3011393277 creator A5019107660 @default.
• W3011393277 creator A5043046640 @default.
• W3011393277 creator A5043790585 @default.
• W3011393277 creator A5059269204 @default.
• W3011393277 creator A5061589915 @default.
• W3011393277 creator A5073345894 @default.
• W3011393277 creator A5073819873 @default.
• W3011393277 creator A5081294763 @default.
• W3011393277 creator A5084185195 @default.
• W3011393277 creator A5085352143 @default.
• W3011393277 date "2012-05-20" @default.
• W3011393277 modified "2023-09-23" @default.
• W3011393277 title "A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumors enriched for Epstein-Barr virus (EBV)-related cancers." @default.
• W3011393277 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.3098" @default.
• W3011393277 hasPublicationYear "2012" @default.
• W3011393277 type Work @default.
• W3011393277 sameAs 3011393277 @default.
• W3011393277 citedByCount "0" @default.
• W3011393277 crossrefType "journal-article" @default.
• W3011393277 hasAuthorship W3011393277A5001623814 @default.
• W3011393277 hasAuthorship W3011393277A5017520870 @default.
• W3011393277 hasAuthorship W3011393277A5019107660 @default.
• W3011393277 hasAuthorship W3011393277A5043046640 @default.
• W3011393277 hasAuthorship W3011393277A5043790585 @default.
• W3011393277 hasAuthorship W3011393277A5059269204 @default.
• W3011393277 hasAuthorship W3011393277A5061589915 @default.
• W3011393277 hasAuthorship W3011393277A5073345894 @default.
• W3011393277 hasAuthorship W3011393277A5073819873 @default.
• W3011393277 hasAuthorship W3011393277A5081294763 @default.
• W3011393277 hasAuthorship W3011393277A5084185195 @default.
• W3011393277 hasAuthorship W3011393277A5085352143 @default.
• W3011393277 hasConcept C121608353 @default.
• W3011393277 hasConcept C126322002 @default.
• W3011393277 hasConcept C143998085 @default.
• W3011393277 hasConcept C159047783 @default.
• W3011393277 hasConcept C2522874641 @default.
• W3011393277 hasConcept C2779699572 @default.
• W3011393277 hasConcept C2781375147 @default.
• W3011393277 hasConcept C2993640289 @default.
• W3011393277 hasConcept C502942594 @default.
• W3011393277 hasConcept C71924100 @default.
• W3011393277 hasConceptScore W3011393277C121608353 @default.
• W3011393277 hasConceptScore W3011393277C126322002 @default.
• W3011393277 hasConceptScore W3011393277C143998085 @default.
• W3011393277 hasConceptScore W3011393277C159047783 @default.
• W3011393277 hasConceptScore W3011393277C2522874641 @default.
• W3011393277 hasConceptScore W3011393277C2779699572 @default.
• W3011393277 hasConceptScore W3011393277C2781375147 @default.
• W3011393277 hasConceptScore W3011393277C2993640289 @default.
• W3011393277 hasConceptScore W3011393277C502942594 @default.
• W3011393277 hasConceptScore W3011393277C71924100 @default.
• W3011393277 hasLocation W30113932771 @default.
• W3011393277 hasOpenAccess W3011393277 @default.
• W3011393277 hasPrimaryLocation W30113932771 @default.
• W3011393277 hasRelatedWork W1510797800 @default.
• W3011393277 hasRelatedWork W1984796464 @default.
• W3011393277 hasRelatedWork W2007306075 @default.
• W3011393277 hasRelatedWork W2168216609 @default.
• W3011393277 hasRelatedWork W2175669346 @default.
• W3011393277 hasRelatedWork W2324553589 @default.
• W3011393277 hasRelatedWork W2902924664 @default.
• W3011393277 hasRelatedWork W2971028988 @default.
• W3011393277 isParatext "false" @default.
• W3011393277 isRetracted "false" @default.
• W3011393277 magId "3011393277" @default.
• W3011393277 workType "article" @default.